Turning the Tide on Cancer
Cardiff Oncology is a clinical-stage company with the singular mission of developing new treatment options for cancer patients. Our goal is to overcome resistance, extend duration of response and increase overall survival.
focusing on cancer indications with the greatest medical need for new treatments
Featured News & Events
Jul 12, 2021
Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer
Jul 6, 2021
Cardiff Oncology to Participate in a Fireside Chat at the William Blair Biotech Focus Conference 2021
Jun 28, 2021
Cardiff Oncology Added to the Russell 2000® and other FTSE Russell Indexes
Targeting PLK1, a Key Regulatory Enzyme in Tumor Cell Division
We are developing onvansertib, an oral and highly selective inhibitor of polo-like kinase 1 (PLK1) for the treatment of cancers with the greatest need for new treatment options.
PLK1 is over-expressed in most cancers. Inhibition of PLK1 causes mitotic arrest and subsequent cell death. Emerging data demonstrates that PLK1 is also a key regulator of cellular functions beyond mitosis that are essential for tumor growth.
Targeting a Key Regulatory Enzyme in Tumor Cell Division
We are developing onvansertib, an oral and highly selective inhibitor of polo-like kinase 1 (PLK1), which is over expressed in most cancers.
Our Clinical Programs
Zytiga-Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Adding onvansertib to daily Zytiga® to overcome resistance, extend treatment response and overall survival.
KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
Combining onvansertib with FOLFIRI/Avastin® to improve efficacy by increasing duration of response and overall survival.
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Leveraging the synergy of onvansertib to increase duration and response of overall survival.